Threshold Pharmaceuticals
Founded Year
2001Stage
Merger | MergedTotal Raised
$50.8MAbout Threshold Pharmaceuticals
Threshold Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that offers broad potential to treat most solid tumors and certain other diseases. By selectively targeting tumor and certain other diseased cells, Threshold's pipeline of drug candidates holds promise to be more effective and less toxic to healthy tissues than conventional drugs. Threshold's initial clinical focus is the treatment of cancer and benign prostatic hyperplasia, or BPH, a disease afflicting tens of millions of men worldwide.
Missing: Threshold Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Threshold Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Threshold Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Threshold Pharmaceuticals is included in 2 Expert Collections, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
1,568 items
Threshold Pharmaceuticals Patents
Threshold Pharmaceuticals has filed 26 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/18/2015 | 9/1/2020 | Transcription factors, Experimental cancer drugs, Oncology, Molecular biology, Antineoplastic drugs | Grant |
Application Date | 11/18/2015 |
|---|---|
Grant Date | 9/1/2020 |
Title | |
Related Topics | Transcription factors, Experimental cancer drugs, Oncology, Molecular biology, Antineoplastic drugs |
Status | Grant |
Latest Threshold Pharmaceuticals News
Jul 28, 2018
Threshold Pharmaceuticals Inc MTEM Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250 11:36 EDT 28 Jul 2018 | BioPortfolio Reports Summary Threshold Pharmaceuticals Inc Threshold is a biotechnology company that discovers and develops tumourtargeted therapies. The company's clinical pipeline includes THCR406, MAESTRO, THCR413, THCR408, THIST4003, THIST4004, THCR410, THCR407 and THIST4001. Its products include evofosfamide, TH4000 and [18F]HX4. Threshold's evofosfamide and TH4000 are under evaluation for the treatment of a variety of tumor types. Threshold offers evofosfamide is a investigational hypoxiaactivated prodrug. The company's [18F]HX4 is an inlicensed positron emission tomography imaging agent for hypoxia. Its clinical trials are used in the treatment of diseases such as soft tissue sarcoma, pancreatic cancer, nonsquamous nonsmall cell lung cancer, advanced melanoma, multiple myeloma and advanced solid tumours, among others. The company operates in the US and Germany. Threshold is headquartered in South San Francisco, California, the US. Threshold Pharmaceuticals Inc MTEM Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Threshold Pharmaceuticals Frequently Asked Questions (FAQ)
When was Threshold Pharmaceuticals founded?
Threshold Pharmaceuticals was founded in 2001.
Where is Threshold Pharmaceuticals's headquarters?
Threshold Pharmaceuticals's headquarters is located at 1300 Seaport Boulevard, Redwood City.
What is Threshold Pharmaceuticals's latest funding round?
Threshold Pharmaceuticals's latest funding round is Merger.
How much did Threshold Pharmaceuticals raise?
Threshold Pharmaceuticals raised a total of $50.8M.
Who are the investors of Threshold Pharmaceuticals?
Investors of Threshold Pharmaceuticals include Molecular Templates, Sutter Hill Ventures, Three Arch Partners, Tang Capital Management, Heights Capital Management and 10 more.
Who are Threshold Pharmaceuticals's competitors?
Competitors of Threshold Pharmaceuticals include Albireo Pharma, ChemoCentryx, Longevica, Acceleron Pharma, Clarus Therapeutics, MaxCyte, Molmed, Portola Pharmaceuticals, Trellis Bioscience, Array Biopharma and 63 more.
Compare Threshold Pharmaceuticals to Competitors
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.
Trellis Bioscience provides health care products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.